|
Sep 27
|
Down -17.96% in 4 Weeks, Here's Why Revance Therapeutics (RVNC) Looks Ripe for a Turnaround
|
|
May 24
|
Revance Therapeutics (RVNC) Loses -18.85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
|
May 10
|
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q1 2024 Earnings Call Transcript
|
|
May 10
|
Revance Therapeutics Reports Q1 2024 Financial Results: Revenue Growth Amidst Rising Operating ...
|
|
May 9
|
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Lags Revenue Estimates
|
|
May 9
|
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
|
|
May 9
|
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia
|
|
May 2
|
Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
|
|
Apr 12
|
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
|
|
Apr 12
|
Revance Therapeutics, Inc. (NASDAQ:RVNC) is favoured by institutional owners who hold 63% of the company
|
|
Mar 27
|
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 4
|
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
|
|
Mar 4
|
Revance Announces Proposed Public Offering of Common Stock
|
|
Sep 19
|
Former IBD 50 Stock Revance Implodes As Its 'Prestige' Plan Goes Up In Smoke
|
|
Sep 19
|
Revance Provides Corporate Update at Investor Day
|
|
Sep 6
|
3 Healthcare Stocks to Sell in September Before They Crash & Burn
|
|
Sep 6
|
Revance Therapeutics (RVNC): A Smart Investment or a Value Trap? An In-Depth Exploration
|
|
Aug 22
|
‘Load Up,’ Says Goldman Sachs About These 2 ‘Strong Buy’ Stocks
|
|
Aug 22
|
Revance to Host Investor Day on September 19, 2023
|
|
Jul 13
|
10 Best Revenue Growth Stocks to Buy
|